Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | LPO | P22079 | 3/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364700 | 1.00 | SLC2A1 (0.58) | SLC2A1LPOPLAULMNATP53 | |
| SCHEMBL17067756 | 0.85 | LPO (0.57) | SLC2A1LPOPLAULMNATP53 | |
| SCHEMBL3510208 | 0.85 | PLAU (0.51) | SLC2A1LPOPLAUPLGHTR6 | |
| SCHEMBL30365128 | 0.85 | PLAU (0.51) | SLC2A1LPOPLAUPLGHTR6 | |
| SCHEMBL15712272 | 0.85 | HDAC8 (0.60) | PLAULMNATP53MAPTKMT2A | |
| SCHEMBL23902663 | 0.83 | PLAU (0.57) | SLC2A1PLAULMNATP53MAPT | |
| SCHEMBL30364651 | 0.83 | PLAU (0.57) | SLC2A1PLAULMNATP53MAPT | |
| SCHEMBL30218812 | 0.83 | KMT2A (0.63) | SLC2A1LPOLMNATP53MAPT | |
| SCHEMBL6087249 | 0.83 | KMT2A (0.63) | SLC2A1LPOLMNATP53MAPT | |
| SCHEMBL30241534 | 0.81 | HTR6 (0.66) | SLC2A1PLAUHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | disclosed |
| EP-4132907-A1 | (1 H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | disclosed |
| EP-3892614-A1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2021-10-13 | — | — | EP | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | disclosed |
| US-9187458-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| CN-101365695-A | Quinazoline derivatives as anticancer agents | ASTRAZENECA AB (SE) | 2009-02-11 | — | — | CN | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | SLC2A1 1306/4885LPO 4297/4885PLAU 3721/4885 |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | SLC2A1 1417/4885LPO 3825/4885PLAU 4106/4885 |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | SLC2A1 1306/4885LPO 4297/4885PLAU 3721/4885 |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | YAP1, YES1, TEAD1 | SLC2A1 4123/4885LPO 4393/4885PLAU 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.